Tagrisso
Sep 15, 2026
TAGRISSO Delivers Landmark Eight-Year Survival Outcomes in Early-Stage EGFR-Mutated Lung Cancer; Scholar Rock Receives FDA Approval for ISEMBYLD; Pharming’s Joenja Receives FDA Approval as First U.S. Treatment for Children With APDS; AbbVie Reports Positive Phase 3 Results for Atogepant in Menstrual Migraine; Rezera’s Ruvonoflast Delivers Positive Inflammation Results with Favorable Safety in RESOLVE-1
TAGRISSO Demonstrates Eight-Year Landmark Survival Benefit for Patients with Early-Stage EGFR-Mutated Lung Cancer Updated exploratory findings from the Phase III ADAURA trial demonstrated that AstraZeneca’s Tagrisso (osimertinib) continued to provide a sustained and clinically meaningful overall survival (OS) be...
Read More...
Nov 29, 2024
Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses
Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
